P2RX7 and melanoma: Accordingly, the efficacy of P2X7 blockers in reducing cancer growth and dissemination was demonstrated in several preclinical models of melanoma [69,78,79], neuroblastoma [72], breast [74,76,80], prostate [77], and pancreatic carcinoma [81], mesothelioma [82], and leukemia [42,69].